Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Program Overview

In recent years, several novel therapeutic classes for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including antibody-drug conjugates, CAR T, and most recently, bispecific T-cell engaging antibodies have emerged. During this symposium, a panel of clinical experts will present the latest data on these therapeutic advances. They will also discuss the integration of these treatments in clinical practice while a patient with R/R DLBCL shares key aspects of their therapeutic journey.

Hybrid Friday Satellite Symposium on R/R DLBCL,
Preceding the 65th ASH Annual Meeting and Exposition

December 8, 2023 3:00 PM – 6:00 PM PT

*Register to Attend In-person or to Attend Virtually

2.0 CE Credit(s)

Target Audience

Hematology, hematology/oncology, oncology clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate data on additional novel therapeutic classes when managing patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
  • Utilize key evidence on CAR T-cell therapies that target CD19 when selecting treatment for individuals with R/R DLBCL
  • Apply available data on bispecific antibodies directed against CD20 and CD3 when personalizing therapy for patients with R/R DLBCL

Activity Faculty

Joshua Brody, MD

Joshua Brody, MD

Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY

Lorenzo Falchi, MD

Lorenzo Falchi, MD

Assistant Attending, Lymphoma Service and Cellular Therapy Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor, Medicine
Weill Cornell Medical College
New York, NY

Lori A. Leslie, MD

Lori A. Leslie, MD

Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia
Associate Professor, Medicine
Hackensack Meridian School of Medicine
Hackensack, NJ

Provider Statement

This activity is provided by RMEI Medical Education, LLC.

Supporter Statement

This activity is supported by an educational grant from Genmab US, Inc. and AbbVie.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2023. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources